S1P may be a potential target for cerebral blood alterations
Sphingosine-1 phosphate was found to regulate blood glow in cerebral blood vessels in mice, presenting a potential therapeutic target.
List view / Grid view
Sphingosine-1 phosphate was found to regulate blood glow in cerebral blood vessels in mice, presenting a potential therapeutic target.
Researchers have uncovered a signalling pathway associated with glutamatergic synapse degeneration in the brains of mice with Alzheimer’s.
A drug called CMS121 given to mice with Alzheimer's-like disease treated their memory loss, allowing them to perform the same as healthy control mice in tests.
A new compound named L1 has demonstrated success in mice, by reducing neuroinflammation and decreasing the levels of amyloid plaques, showing potential as an Alzheimer's treatment.
Novel promoters based on those in the herpes viruses, enabled delivery of larger genes and increased the period they were active in the nervous system.
Drug Target Review discusses how NETSseq, a novel profiling technology, is bringing new insights to neurodegenerative and psychiatric diseases.
A group of researchers has synthesised a new class of ligands which bind with high affinity to imidazoline I2 receptors, a drug target for Alzheimer's disease.
Researchers have discovered that neuronal necrosis occurs in Alzheimer's earlier than previously though and revealed the YAP protein as a potential target.
Researchers have engineered a chip which allows 3D modelling of the blood-brain-barrier and has provided insight into how astrocytes facilitate transport of molecules.
Research into age-related chronic inflammatory disorders has identified an ‘off switch’ on the NLRP3 inflammasome that could be targeted in new therapies.
A new experimental drug was shown by researchers to restore natural brain rhythms in mouse models of Alzheimer’s and promote learning and memory.
Researchers have developed a screening system and identified a set of compounds that protect neuronal mitochondria in mice.
Researchers have created a new combination vaccine therapy that can induce strong immune responses against tau and Aβ pathologies seen in Alzheimer’s in bigenic mice.
A study has demonstrated that exosomes can be used as nanocarriers for therapeutic contents, as a new type of gene therapy.
A study has demonstrated that inducing brain vessel pulsations helps to clear substances from the brains of mice, so could be used to stop amyloid-β build up in the development of Alzheimer’s.